Literature DB >> 25092692

Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis.

Feng Sun1, Qiaoling Ruan2, Jiali Wang2, Shu Chen2, Jialin Jin2, Lingyun Shao2, Ying Zhang3, Wenhong Zhang2.   

Abstract

We conducted a retrospective cohort study of patients with MRC grade II/III tuberculous meningitis (TBM) who accepted a background antitubercular regimen (BR) with or without linezolid (LZD). At the 4th week, the LZD-BR group achieved a faster and higher percentage of Glasgow coma scale recovery and temperature recovery, a higher cerebrospinal fluid (CSF)/blood glucose ratio, and lower CSF white blood cell counts than did the BR group. Short-term linezolid supplementation may be a more effective treatment for life-threatening TBM.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25092692      PMCID： PMC4187991          DOI： 10.1128/AAC.02784-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome.

Authors:  Flavia Brancusi; Jeremy Farrar; Dorothee Heemskerk
Journal:  Future Microbiol       Date:  2012-09       Impact factor: 3.165

2.  Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.

Authors:  Bent von der Lippe; Per Sandven; Oddbjørn Brubakk
Journal:  J Infect       Date:  2006-02       Impact factor: 6.072

3.  Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.

Authors:  I-Nae Park; Sang-Bum Hong; Yeon-Mok Oh; Mi-Na Kim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Dong Soon Kim; Won Dong Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2006-07-19       Impact factor: 5.790

4.  Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

Authors:  Holly A Anger; Felicia Dworkin; Saarika Sharma; Sonal S Munsiff; Diana M Nilsen; Shama D Ahuja
Journal:  J Antimicrob Chemother       Date:  2010-02-11       Impact factor: 5.790

5.  A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Authors:  G B Migliori; B Eker; M D Richardson; G Sotgiu; J-P Zellweger; A Skrahina; J Ortmann; E Girardi; H Hoffmann; G Besozzi; N Bevilacqua; D Kirsten; R Centis; C Lange
Journal:  Eur Respir J       Date:  2009-03-12       Impact factor: 16.671

6.  Linezolid in the treatment of multidrug-resistant tuberculosis.

Authors:  G F Schecter; C Scott; L True; A Raftery; J Flood; S Mase
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

7.  Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.

Authors:  Reynaldo Dietze; David Jamil Hadad; Bryan McGee; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; Charles A Peloquin; Denise F Johnson; Sara M Debanne; Kathleen Eisenach; W Henry Boom; Moises Palaci; John L Johnson
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

Review 8.  Peripheral neuropathy associated with prolonged use of linezolid.

Authors:  Adam M Bressler; Shanta M Zimmer; Jane L Gilmore; Jyoti Somani
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

9.  PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.

Authors:  Ramandeep Singh; Ujjini Manjunatha; Helena I M Boshoff; Young Hwan Ha; Pornwaratt Niyomrattanakit; Richard Ledwidge; Cynthia S Dowd; Ill Young Lee; Pilho Kim; Liang Zhang; Sunhee Kang; Thomas H Keller; Jan Jiricek; Clifton E Barry
Journal:  Science       Date:  2008-11-28       Impact factor: 63.714

10.  Tuberculous meningitis: diagnosis and treatment overview.

Authors:  Grace E Marx; Edward D Chan
Journal:  Tuberc Res Treat       Date:  2011-12-21
View more
  19 in total

Review 1.  Tuberculous Meningitis in Children and Adults: New Insights for an Ancient Foe.

Authors:  Alyssa Mezochow; Kiran Thakur; Christopher Vinnard
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-20       Impact factor: 5.081

2.  Key considerations in the pharmacotherapy of tuberculous meningitis.

Authors:  Sean Wasserman; Angharad Davis; Robert J Wilkinson; Graeme Meintjes
Journal:  Expert Opin Pharmacother       Date:  2019-07-15       Impact factor: 3.889

3.  Long term outcomes of patients with tuberculous meningitis: The impact of drug resistance.

Authors:  Emily E Evans; Teona Avaliani; Mariam Gujabidze; Tinatin Bakuradze; Maia Kipiani; Shorena Sabanadze; Alison G C Smith; Zaza Avaliani; Jeffrey M Collins; Russell R Kempker
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

Review 4.  Tuberculosis in Children.

Authors:  Devan Jaganath; Jeanette Beaudry; Nicole Salazar-Austin
Journal:  Infect Dis Clin North Am       Date:  2022-03       Impact factor: 5.905

5.  Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness.

Authors:  Russell R Kempker; Alison G C Smith; Teona Avaliani; Mariam Gujabidze; Tinatin Bakuradze; Shorena Sabanadze; Zaza Avaliani; Jeffrey M Collins; Henry M Blumberg; Mohammad H Alshaer; Charles A Peloquin; Maia Kipiani
Journal:  Clin Infect Dis       Date:  2022-09-10       Impact factor: 20.999

6.  Tuberculous meningitis: a roadmap for advancing basic and translational research.

Authors:  Sanjay K Jain; David M Tobin; Elizabeth W Tucker; Vishwanath Venketaraman; Alvaro A Ordonez; Lakshmi Jayashankar; Omar K Siddiqi; Dima A Hammoud; Nemani V Prasadarao; Matyas Sandor; Richard Hafner; Zsuzsanna Fabry
Journal:  Nat Immunol       Date:  2018-06       Impact factor: 25.606

7.  Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.

Authors:  Elizabeth W Tucker; Lisa Pieterse; Matthew D Zimmerman; Zarir F Udwadia; Charles A Peloquin; Maria Tarcela Gler; Shashank Ganatra; Jeffrey A Tornheim; Prerna Chawla; Janice C Caoili; Brittaney Ritchie; Sanjay K Jain; Véronique Dartois; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

8.  Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.

Authors:  Shashikant Srivastava; Devyani Deshpande; Jotam Pasipanodya; Eric Nuermberger; Soumya Swaminathan; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2016-11-01       Impact factor: 9.079

9.  Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM].

Authors:  Angharad G Davis; Sean Wasserman; Mpumi Maxebengula; Cari Stek; Marise Bremer; Remy Daroowala; Saalikha Aziz; Rene Goliath; Stephani Stegmann; Sonya Koekemoer; Amanda Jackson; Louise Lai Sai; Yakub Kadernani; Thandi Sihoyiya; C Jason Liang; Lori Dodd; Paolo Denti; Thomas Crede; Jonathan Naude; Patryk Szymanski; Yakoob Vallie; Ismail Banderker; Shiraz Moosa; Peter Raubenheimer; Rachel P J Lai; John Joska; Sam Nightingale; Anna Dreyer; Gerda Wahl; Curtis Offiah; Isak Vorster; Sally Candy; Frances Robertson; Ernesta Meintjes; Gary Maartens; John Black; Graeme Meintjes; Robert J Wilkinson
Journal:  Wellcome Open Res       Date:  2021-06-01

10.  Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.

Authors:  A G C Smith; M Gujabidze; T Avaliani; H M Blumberg; J M Collins; S Sabanadze; T Bakuradze; Z Avaliani; R R Kempker; M Kipiani
Journal:  Int J Tuberc Lung Dis       Date:  2021-08-01       Impact factor: 3.427
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.